



Mini review

Modulation of L-type calcium channels in Alzheimer’s disease: A potential therapeutic target

Chelsea A. Crossley, Vishaal Rajani, Qi Yuan *

Biomedical Sciences, Faculty of Medicine, Memorial University, Canada

ARTICLE INFO

Article history:

Received 15 October 2022
Received in revised form 22 November 2022
Accepted 23 November 2022
Available online 26 November 2022

Keywords:

L-type calcium channel
Aging
Alzheimer’s disease
 β -Amyloid
Tau

ABSTRACT

Calcium plays a fundamental role in various signaling pathways and cellular processes in the human organism. In the nervous system, voltage-gated calcium channels such as L-type calcium channels (LTCCs) are critical elements in mediating neurotransmitter release, synaptic integration and plasticity. Dysfunction of LTCCs has been implicated in both aging and Alzheimer’s Disease (AD), constituting a key component of calcium hypothesis of AD. As such, LTCCs are a promising drug target in AD. However, due to their structural and functional complexity, the mechanisms by which LTCCs contribute to AD are still unclear. In this review, we briefly summarize the structure, function, and modulation of LTCCs that are the backbone for understanding pathological processes involving LTCCs. We suggest targeting molecular pathways up-regulating LTCCs in AD may be a more promising approach, given the diverse physiological functions of LTCCs and the ineffectiveness of LTCC blockers in clinical studies.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Contents

1. Introduction	12
2. LTCC overview	12
2.1. Structure and function	12
2.2. LTCC drug targeting and modulation	13
3. LTCC in synaptic plasticity and learning: Effects of aging and implications in AD	14
3.1. LTCC-mediated plasticity changes in aging	14
3.2. LTCC modulation in Alzheimer’s disease	14
3.2.1. LTCC and β -amyloid	14
3.2.2. LTCC and tau	15
4. Summary and overview	16
Funding	16
CRediT authorship contribution statement	16
Declaration of Competing Interest	16
References	16

Abbreviations: A β , β -amyloid; AC, adenylyl cyclase; AD, Alzheimer’s Disease; AHP, afterhyperpolarization; AR, adrenoceptor; BIN1, bridging integrator 1; BTZs, benzothiazepines; CaMKII, calmodulin-dependent protein kinase II; CDF, calcium-dependent facilitation; CDI, calcium-dependent inactivation; DHP, dihydropyridine; LTCC, L-type calcium channels; LTD, long-term depression; LTP, long-term potentiation; NFT, neurofibrillary tangles; NMDAR, N-methyl-D-aspartate receptor; PAA, phenylalkylamines; PKA, protein kinase A; PKC, protein kinase C; PKG, protein kinase G; SFK, Src family kinase; VSD, voltage sensing domain.

* Corresponding author at: Biomedical Sciences, Faculty of Medicine, Memorial University, St. John’s, NL A1B 3V6, Canada.

E-mail address: qi.yuan@med.mun.ca (Q. Yuan).

<https://doi.org/10.1016/j.csbj.2022.11.049>

2001-0370/© 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

A long-standing hypothesis for the etiology of Alzheimer's disease (AD) is the calcium hypothesis: a disruption in calcium homeostasis and high intracellular calcium concentration are associated with β -amyloid (A β) and neurofibrillary tangles (NFT), which alter synaptic plasticity and cognitive function, leading to neural degeneration and eventual cell death [43,83]. Aging and AD are associated with chronic elevations in Ca^{2+} influx via L-type calcium channels (LTCC). LTCC blockers have been successful in ameliorating AD pathology in animal models [34,121]. Nimodipine, which readily passes the blood–brain barrier, reversed some of the cognitive impairment in dementia patients in earlier studies [8,57,164]. However, inconsistent effects of LTCC blockers have been reported in recent years [4]. Although LTCC hyperfunction and associated calcium imbalance have been extensively studied in aging [82,84,90], how alteration of LTCC function occurs in AD and contributes to AD pathology are much less understood. Thus, evidence calls for further investigation of the role of LTCCs in AD and the potential therapeutic benefits of LTCC blockers. In this review, we first summarize the structure and function of LTCCs and drug targeting by LTCC blockers. We then discuss changes of LTCCs in aging and AD, and interactions of LTCCs with key pathogenic molecules A β and tau, with the hope of shedding light on intervention strategies in AD.

2. LTCC overview

2.1. Structure and function

LTCCs are the largest group of voltage-gated calcium channels. LTCCs are grouped based on their pharmacological responses to dihydropyridine (DHP) antagonists and agonists and their electrophysiological profiles [99,180]. LTCCs consist of four different pore-forming α_1 subunits named Cav1.1 (α_{1S}), Cav1.2 (α_{1C}), Cav1.3 (α_{1D}), and Cav1.4 (α_{1F}), associated with auxiliary subunits α_2 - δ , β , and γ [9,151,180]. The Cav1.1 isoform, encoded by the CACNA1S gene,

is found in skeletal muscle. It is involved in excitation–contraction coupling [9,132,152]. Mutations of Cav1.1 have been implicated in malignant hyperthermia and hypokalemic periodic paralysis [59,149]. The Cav1.4 isoform, encoded by the CACNA1F gene, can be found in the retina and is involved in photoreceptor transmitter release [110,111]. Mutations of the Cav1.4 isoform are linked to night blindness [11,87]. The Cav1.2 and Cav1.3 isoforms are primarily expressed in the heart and brain and they have been implicated in neurological disorders such as autism, bipolar disorder and Timothy's Syndrome (see reviews [120,149,180]). As such, they are the primary focus of this review.

The Cav1.3 isoform, encoded by the CACNA1D gene, can be found in the neuroendocrine system, neurons, cochlea and cardiac pacemaker cells and plays a role in cardiac pacemaking, synaptic regulation, excitation–transcription coupling, hearing and hormone release (see reviews [120,149,180]). Finally, the Cav1.2 isoform is encoded by the CACNA1C gene on chromosome 12p13 [138], and can be found in the heart, endocrine system, as well as neurons [180]. In the nervous system, Cav1.2 plays an important role in various processes including activation of calcium-dependent ions, enzymes and potassium channels [74,130]. Furthermore, they are thought to be important for the initiation of calcium-dependent gene transcription events such as excitation–transcription coupling, synaptic integration and plasticity, and dendritic development [47,174,180]. In addition, approximately 80 % of LTCCs in the hippocampus, a primary memory center of the brain, are comprised of the Cav1.2 isoform and contribute to up to half of the total calcium current in the region [16,58,68]. Cav1.2 subunits are expressed on both the somatic and dendritic regions of hippocampal neurons including synapses [68,107].

LTCCs are heteromultimers composed of a pore forming α_1 subunit which mediates the pharmacological and gating properties of the channel [69,151,180] (Fig. 1). The α_1 subunit is made up of six transmembrane α -helices (S1–S6) [145,153,178]. The S1–S4 helices make up the voltage sensing domain (VSD) of the transmembrane domain, whereas S5 and S6 and their connecting P loops (P1 and P2) make up the calcium conducting pore domain and selectivity




Fig. 1. Cross-section of the LTCC. A 3D schematic is shown in the upper left insert. The LTCC consists of four transmembrane α_1 subunits (I–IV) and four auxiliary subunits, α_2 , δ , β and γ . Each α_1 subunit is comprised of 6 transmembrane helices: S1–S6, with S1–S4 involved in voltage sensing and S5–S6 making up the calcium pore domain [178]. The auxiliary γ subunit, consisting of 4 transmembrane domains binds to the α_1 subunit [31] while the β subunit binds to the α_1 subunit I–II interaction domain [5]. The extracellular α_2 subunit is linked to the δ subunit via disulfide bridges, and is involved in both trafficking and channel function [49].

filter (Fig. 1). Upon membrane depolarization, S4 is rearranged to have a positive arginine or lysine at every third residue and the VSD senses this change [30]. That information is then transmitted to S5 via the connecting cytosolic linker. Finally, the activation gate formed by the S6 helix opens the channel [30,178]. This conformational change to the activated state allows for selective flow of calcium into the neuron and as calcium ions flow into the cell, the channel slowly returns to a resting closed state. The N- and C-terminals of α_1 contribute to LTCC activation and inactivation via calmodulin interaction domains and LTCC modulating protein binding sites [48,124,171]. α_1 subunits are modulated by G-protein coupled protein kinases via phosphorylation. For example, protein kinase A (PKA) is known to mediate the opening and closing of the channel. When the α_1 subunit is phosphorylated by PKA in the hippocampus at serine 1928 proximal to the C terminus, the number of functionally upregulated LTCCs increases [64,66].

In addition to the α_1 subunit, LTCCs have up to four auxiliary subunits (α_2 , β , δ and γ) which are involved in vesicle anchoring, trafficking, regulatory functions and promote expression of LTCCs along the membrane [5,29,178,180] (Fig. 1). The α_2 , δ and β subunits are known to play a role in α_1 subunit trafficking and to influence biophysical properties of the channels [146,178]. The α_2 and δ subunits originate from the same gene. However, during post-translational modification, they are cleaved into separate proteins that are connected by a disulfide bond creating the α_2 - δ subunit. The α_2 component is extracellular and the δ subunit spans the membrane (Fig. 1). The primary function of the α_2 - δ subunit is to stabilize and promote the cell surface expression of LTCCs [40]. The site and mechanism by which α_2 - δ promotes expression is unclear. However, knockout of this subunit results in reduced calcium channel currents in Purkinje neurons, impairing their function [10,50]. While the function of the α_2 - δ is not entirely clear, it is known that they are essential for the relief of neuropathic pain as drugs such as gabapentin and pregabalin bind to α_2 - δ [154]. The β subunit, on the other hand, is localized intracellularly and binds to the α_1 subunit interaction domain at the I-II linker [131,178] (Fig. 1). It has been suggested that this subunit, by binding to the α_1 subunit, promotes the posttranslational events that ensure the insertion of only mature calcium channels into the lipid bilayer of the plasma membrane [15]. In addition to its involvement in trafficking, the β subunit has also been implicated in the modulation of LTCCs via phosphorylation of PKA and calmodulin-dependent protein kinase II (CaMKII). Finally, the γ subunit was initially not found in either Cav1.2 or Cav1.3 isoforms thus it was thought to not present in neurons [3]. However, a γ_2 subunit associated with neuronal Ca^{2+} channels was discovered later [5,80,94]. In contrast to β and α_2 - δ subunits, γ_2 subunit suppresses α_1 subunit activation [80]. The mutation of γ_2 subunit is associated with absence epilepsy [94]. A knock out mouse model suggested γ subunit may function to limit the amount of Ca^{2+} entry during stimulation of skeletal muscle [62].

2.2. LTCC drug targeting and modulation

LTCCs can be targeted by three groups of drugs including phenylalkylamines (PAAs), benzothiazepines (BTZs), and DHPs [120,180]. Computational LTCC models created using the crystal structure of the KvAP channel [162] have been instrumental in drug targeting studies. These models have since been used to better understand the binding of BTZs [162], DHPs [163] and PAAs [32] to LTCCs. Using KvAP-based models, Zhorov's group was able to determine that all three ligands bind near the S5–S6 helices of domains III and IV. However, the DHPs and BTZs bind to LTCCs extracellularly whereas PAAs bind intracellularly through the open activation gate [32,162–163].

DHP derivatives including amlodipine, nifedipine, clevidipine, felodipine, and isradipine, are most commonly used to treat cardiovascular diseases such as angina, vasodilation or hypertension [150]. However, nimodipine, another DHP, readily passes the blood–brain barrier, making it a therapeutic measure for neuronal calcium dysregulation. The DHPs act on S6 by binding to Tyr1152, Ile1153, Ile1156 and Met1161 of the third transmembrane domain of the α_1 subunit and to Asn1472 of the fourth transmembrane domain [150]. These DHPs act as LTCC antagonists, and they bind to the pore-forming α_1 subunit in the inactivated state to prevent calcium influx by shifting the LTCC towards the closed state [139].

The activity of LTCCs can not only be regulated by membrane depolarization [69,89], but also by protein kinase phosphorylation [29,52,56,66,73,93,122,179]. For example, LTCC activity is, in part, modulated by interactions with calmodulin or calcium/CaMKII [52,73,93,179]. Calcium-dependent inactivation (CDI) occurs when the influx of calcium results in the binding of calcium to calmodulin on the C-terminus and this leads to a change in channel configuration [123,184]. This CDI phenomenon is a negative feedback mechanism that acts as a safety mechanism to prevent prolonged dangerous influx of calcium and it is crucial for post-action potential (AP) repolarization [13,112]. However, CDI can be impaired with age which results in AP prolongation. More specifically, there is a prolonged post-burst slow afterhyperpolarization (AHP) which is primarily a calcium-dependent potassium current. Thus it takes longer for the cell to repolarize to baseline [43,114,126,161]. This prolonged AHP is linked to deficits in hippocampal-dependent learning and memory tasks [106,113,161]. Furthermore, the prolonged slow AHP in aged animals can be rescued through the use of LTCC blockers such as nimodipine [114]. This suggests that LTCCs are involved in age-related prolongation of repolarization and limits further firing of neurons. Alternatively, calcium-dependent facilitation (CDF), also arises from the interaction of calcium ions, calmodulin and the α_1 subunit, yet has the opposite effect of enhancing the calcium flux. CDF is mediated by the CaMKII-dependent phosphorylation of Cav1.2 at Thr498 of the β_{2a} subunit and the tethering of the CaMKII to α_{1c} subunit [2,52,73,93]. It plays an important role in synaptic plasticity and excitation–contraction coupling [21,41,47]. CaMKII is a kinase that is essential for learning and memory [100] and the inhibition of CaMKII prevents phosphorylation, which, in turn, prevents CDF [179,185,186]. Its tethering to the α_1 subunit allows for control of the feedforward CDF mechanism [73].

As indicated above, phosphorylation is an important process that mediates LTCC function. Several other protein kinases besides CaMKII are critical as well. It is well established that PKA and protein kinase C (PKC) mediated phosphorylation can affect pore structure, thus affecting calcium influx [108,122,127,128]. Both PKA and PKC can phosphorylate Cav1.2 at Ser1928 on the α_{1c} subunit. Phosphorylation of Cav1.2 on Ser1928 by PKA augments Cav1.2 activity and synaptic plasticity [122,128]. Cav1.3 current is also elevated by cAMP/PKA signaling in cardiac [183], endocrine cells [103,167], and neurons [86]. The dominate phosphorylation sites in Cav1.3 for PKA are Ser1964 and Ser1743 and PKA phosphorylation of Cav1.3 requires β subunit [167]. In the neonatal hippocampus, PKC activation mediates GABA_B enhancement of LTCC currents, alongside PKA [22]. Additionally, in retinal epithelial cells, PKC blockade reduces LTCC currents [148]. In contrast, Cav1.2 and Cav1.3 are down-regulated by nitric oxide/cGMP/protein kinase G (PKG) pathway in cardiac and endocrine cells [103,167]. The opposite modulations by PKA and PKG signaling in these cells enable fine-tuning of cellular functions.

Moreover, protein tyrosine kinases, such as Src family kinases (SFKs), also have the ability to regulate neurotransmitter release via SFK-mediated phosphorylation of the α_{1c} subunit [51]. Evans

and Pocock (2009), using cultured rat cerebellar cells, demonstrated that LTCC-mediated exocytosis requires tyrosine phosphorylation by a SFK and that inhibiting SFK through the use of PP1 prevents exocytosis [56]. While LTCC-mediated exocytosis is an important process in response to oxidative stress in the hippocampus, tyrosine phosphorylation of α_{1C} over-enhances this process which can lead to neuronal death. Hou et al. [71] demonstrated that LTCCs are functionally upregulated in post-ischemic brains, and this further enhances phosphorylation by SFKs and creates a positive feedback loop leading to a dangerous intracellular calcium overload [71]. However, how SFKs are activated and how they modulate LTCCs are still not clear. One possibility is that SFKs, such as Src, is activated by PKC via Pyk2 [42,95,135]. Stimulation of PKC triggers dimerization and subsequent *trans*-autophosphorylation of Pyk2, promoting binding and activation of Src [42].

Src increases LTCC currents in smooth muscle cells [65,72], retinal pigment epithelial cells [148], and neurons [12,54]. Phosphorylation of Cav1.2 at tyrosine residue Y2122 is involved in the upregulation of Cav1.2 activity by Src in rat neurons [12]. However, the target sites for Src in Cav1.2 in other species including human and rabbits are unknown, despite that Src activation enhances LTCC currents in both species [72,148].

3. LTCC in synaptic plasticity and learning: Effects of aging and implications in AD

3.1. LTCC-mediated plasticity changes in aging

With aging, the expression of LTCCs in the hippocampus increases [107,116,159] which, subsequently, increases the calcium current [28,46,159]. However, it is not simply the overall protein level of the Cav1 subunit that is overexpressed in aged animals. In fact, Nunez-Santana et al. [116] demonstrated that protein levels in whole tissue lysates of Cav1.2 and Cav 1.3 subunits are reduced in the aged CA1, CA3 and DG of the hippocampus in comparison to adult animals. In addition, there are no changes in Cav1.2 and Cav1.3 mRNA levels with age. The calcium dysregulation occurs as a result of an increased surface ratio of Cav1.2 in the CA1 and CA3 regions, and of Cav1.3 only in the CA3 region. In addition, the immunoreactivity of Cav1.2 is heightened in the somatic portion of these regions [116], which has been confirmed by a recent study [107]. Furthermore, LTCC activity is increased approximately 5-fold when they are phosphorylated [81,141,142]. Cav1.2 phosphorylation at Ser1928 is increased with age which enhances influx of calcium into the neuron [38]. However, the activation of LTCCs is phosphorylation site specific and phosphorylation at other sites such as Ser533 inhibits LTCC activity [77]. Another report showed increased expression of Cav1.3 in CA1 region was associated with working memory impairment in aged rats [168].

There are two ways that LTCCs can affect plasticity. On the one hand, LTCC activation can directly mediate long-term potentiation (LTP) or long-term depression (LTD). *N*-methyl-d-aspartate receptors (NMDARs) and LTCCs are the two major calcium mediators for synaptic plasticity, which initiate diverse calcium-dependent signaling cascades critical for memory formation. Changes in these receptors/channels with age directly influence synaptic plasticity and learning capacity across different developmental stages. In hippocampal CA1 neurons, both the decreased tendency for LTP and the increased tendency for LTD during aging are attributed to LTCC hyperfunction and concomitant reduced functionality of NMDARs [88,115]. Furthermore, the age-related increase in LTCCs is associated with a shift in the forms of synaptic plasticity in aged rats, which exhibit a reduced NMDAR-dependent and increased LTCC-dependent LTP and LTD at CA3-CA1 synapses [19,92,144].

This age-related modification of the expression and function of LTCCs in hippocampal neurons could contribute to dysregulated calcium homeostasis, resulting in synaptic dysfunction and cognitive decline [115], although a protective role of increased LTCC plasticity in aging has also been proposed [19,92]. Recently, we demonstrated that similarly to the hippocampus [19,92,134], there is an age-dependent increase in the contribution of LTCCs to LTD in the piriform cortex (PC), concurrent with a decreased role for NMDARs [129]. Moreover, inhibition of LTCCs in the aged PC blocks LTD [129] and could consequently enhance learning [107]. LTCC dysregulation is suggested in models for age-related cognitive decline [157] and is likely involved in AD.

On the other hand, LTCCs may directly influence learning and memory formation by altering neuronal excitability. In hippocampal CA1 neurons, calcium influx through LTCCs activates calcium-activated potassium channels, increasing AHPs and reducing neuronal excitability [44,46,107]. Consequently, the threshold for NMDAR-dependent LTP may be elevated [60,61]. Aging augments LTCC current, phosphorylation and AHP as aforementioned [38,44,107,158,159]. Several studies have indicated that the LTCC blockers can act by reducing the slow AHPs in the hippocampus [98,114,126]. This reduction in CA1 AHP has been shown to improve hippocampal-dependent learning [45,119].

3.2. LTCC modulation in Alzheimer's disease

Disruption in calcium homeostasis has been extensively implicated in aging and AD [4,43,83], where there is heightened calcium influx into neurons via LTCCs [53,102,158,159,166,176]. Hyperfunction of LTCCs and resultant increased intracellular calcium can impair neuronal function, adversely affecting synaptic function and plasticity. Several lines of evidence support the notion that LTCC hyperfunction contributes to AD pathogenesis. Coon et al. [33] demonstrated that hippocampal neurons in AD brains show significantly increased binding of isradipine, a DHP ligand, and increased cell loss in AD brains compared to controls. This suggests that the hippocampus, a primary memory center of the brain, is more vulnerable to calcium dysregulation in AD [33]. LTCC blockers have shown beneficial effects in reversing neuronal dysfunction and cognitive impairment in both humans and animal models [34,43,97].

Despite that numerous studies have implicated chronic up-regulation of LTCCs in the etiology of AD, a critical gap in knowledge remains regarding how LTCCs are up-regulated during AD and how LTCC hyperfunction relates to neuropathology. We discuss below emerging evidence of relationship between LTCCs, amyloid and tau. The potential interaction pathways are summarized in Fig. 2. It is noteworthy to point out that besides direct effects on neurons, the LTCC dysregulation of brain vasculature is likely involved in AD pathogenesis. Cerebral hypoperfusion is an important contributor to the cognitive decline in AD [75]. Aging, as the biggest risk factor for AD, is also associated with vascular calcium dysregulation [67]. Heightened function of vascular LTCCs via Ser1928 phosphorylation [104,117] and associated vascular constriction may exacerbate AD pathology [156].

3.2.1. LTCC and β -amyloid

There is conflicting evidence linking A β deposits to LTCC hyperfunction. In cell cultures, A β peptide has been shown to increase LTCC expression [39,85,166,173]. A β was reported to directly associate with α_{1C} subunit and promote trafficking and insertion of LTCC at the plasma membrane [140], or act on β_3 subunit to facilitate Cav1.2 and Cav1.3 surface trafficking [85]. In rat cortical neurons, the expression of human amyloid precursor protein is sufficient to increase LTCC currents, however, the augment of LTCCs is independent of A β [137]. Interestingly, amyloid precursor




Fig. 2. LTCC modulations by A β and tau. A β and tau can interact with β subunits to facilitate Cav1.2 surface trafficking [85,169]. Additionally, A β stimulates β_2 -adrenoceptor (β_2 -ARs)-LTCC complex and enhances PKA phosphorylation of Cav1.2 at S1928 [170]. Tau could exert its effect through Pyk2 and Src/Fyn [14,91,96]. Elevated cytosolic Ca²⁺ and calpain result in tau hyperphosphorylation via GSK-3 β [78]. Calcium influx through LTCCs augments calcium influx into mitochondria, whereas abnormal tau impairs calcium extrusion from mitochondria [23].

protein expression in the cortical neurons enhances AHP and inhibits spontaneous calcium oscillations, similar to the abnormal AHP and disruption of neuronal excitability observed in hippocampal neurons in aging [44,107,158]. However, direct measurement of LTCC current in a transgenic APP/PS1 mouse model failed to show elevation [160].

Besides direct association and interaction with LTCC subunits [85,140], A β can exert its effects on LTCCs through β_2 -adrenoceptors (β_2 -ARs). Soluble A β binds to N terminus of β_2 -adrenoceptors to induce Gs/adenylyl cyclase (AC)/cAMP/PKA signaling [170]. Cav1.2 forms a unique signaling complex with the β_2 -ARs and its effector proteins Gs, AC and PKA [7,37], thus β_2 -ARs signaling can potentially up-regulate LTCC channel activity. Phosphorylation at Ser1928 on Cav1.2 uncouples the β_2 -ARs from Cav1.2 [122]. The existence of this complex suggests that Cav1.2 is a major target for β_2 -ARs, whereby A β engages its effects. Notably, β_2 -ARs are increased in the brains of AD patients, especially within the hippocampus [79]. Epidemiological studies showed reduced incidence of AD correlated with non-selective β -AR antagonist administration [133]. In animal studies, chronic treatment with β_2 -AR blockers reduces A β production [182] and tau pathology [177].

Furthermore, A β stimulates glutamate release and glutamate spillover contributing to perisynaptic activation of glutamatergic receptors [155], which facilitates NMDAR-dependent LTCC dendritic Ca²⁺ spikes [175]. A β -enhanced Cav1.2 activity likely mediates synaptotagmin-3-mediated endocytosis of AMPARs at perisynaptic endocytic zones and facilitates LTD [6]. Indeed, A β 42 oligomers application potentially enhances LTD and impairs LTP in rodent models [136,143]. Altered plasticity, such as enhanced LTD, is correlated with forgetting [6].

Besides neurons, increased LTCC expression is associated with A β plaques in reactive astrocytes in a mouse model [36]. Particularly, up-regulation of Cav1.2 α_1 subunit is dependent on the presence of A β plaques [36]. Blocking LTCCs increases angiogenesis in organotypic brains slices of an A β mouse model [35].

3.2.2. LTCC and tau

While the link between A β and LTCCs requires further investigation, the relationship between tau and LTCC expression is becoming an exciting research avenue. Abnormal persistently phosphorylated soluble tau, termed pre-tangle tau, can begin as early as in childhood and first appears in the brain stem structure locus coeruleus [20]. Pre-tangle tau spreads to the transentorhinal/hippocampus memory pathway over decades before the onset of clinical symptoms. Recent data suggest that soluble pre-tangle tau is the more toxic forms among tau species [24,105]. Cell death and synaptic dysfunction occur in pre-tangle tau mice preceding NFT formation [125,181].

However, how pre-tangle tau drives neurotoxicity is not well understood. There is some evidence that interaction between tau and LTCCs may, at least partially, mediate synaptic dysfunction. In hippocampal neuronal culture, tau mediates bridging integrator 1 (BIN1) association with LTCCs and the shuffling of LTCCs to the plasma membrane [169]. Tau proline-rich domain interacts with both BIN1 and LTCC- β_1 SH3 domains. Recent evidence suggests that LTCC hyperfunction occurs due to tau hyperphosphorylation. In the 3xTG mouse model, there is selective hyperphosphorylation of tau in CA1 and widespread A β [118]. Wang & Mattson [172] found that LTCC amplitude and density were higher in the hippocampal CA1 of aged 3xTG mice compared to wild-type mice [172]. However, in the CA3 and DG regions of the hippocampus, where there is no increase in hyperphosphorylated tau, LTCC amplitude and density does not differ in 3xTG and wild-type mice. This study reinforces that the CA1 is particularly vulnerable to tau pathology, which leads to increased LTCC expression, and highlights the relationship between pre-tangle hyperphosphorylated tau and LTCC hyperfunction in the AD model. Increased LTCC activity is also associated with a mutant tau which is linked to frontotemporal dementia and parkinsonism in SH-SY5Y cell lines [63]. Mice expressing the mutant tau exhibits a larger AHP in dorsal entorhinal neurons [17] and altered intrinsic and synaptic properties in the hippocampus [18], likely due to LTCC hyperfunction associated with the tau mutation.

Interestingly, a recent study by Stan and colleagues [147] suggested that specific human tau isoforms, such as ON4R, enhance LTCC currents in cultured hippocampal neurons. The resultant increase in Ca^{2+} entry is associated with increased medium and slow AHPs. The Cav1.2 and Cav1.3 β_3 subunit that regulates trafficking and biophysical properties of the channel directly associates with ON4R isoform and is required for tau-induced LTCC augmentation [147]. Similarly, expression of human ON4R isoform of tau in *Drosophila* mushroom body increases LTCC expression in the neuronal membrane and results in odor memory deficiency [70]. Correcting LTCC expression to the wild-type level with RNAi knock-down restores memory in the human tau-expressing *Drosophila* [70].

Tau could influence both cytosolic and mitochondrial calcium signaling. A link between tau and LTCCs may be through the SFKs. Src and Fyn phosphorylation of Cav1.2 LTCC has been established [12,54,71,101]. Tau interacts with Src kinases and their activator Pyk2 [14,91,96] and could potentially enhance LTCC activation. Mutant or hyperphosphorylated tau has been associated with increased LTCC currents [63,172] and decreased mitochondrial biogenesis [165]. LTCC activation in turn mediates tau hyperphosphorylation via GSK-3 β , which can be prevented by an LTCC blocker *in vitro* [109]. Additionally, mitochondrial dysfunction and associated alteration in Ca^{2+} homeostasis have emerged as important factors in AD and tauopathy [1,55]. Elevation of cytosolic Ca^{2+} leads to mitochondrial Ca^{2+} uptake via mitochondrial calcium uniporters [1]. MAPT mutant tau inhibits mitochondrial calcium efflux via inhibiting the $\text{Na}^+/\text{Ca}^{2+}$ exchanger and makes neurons more vulnerable to calcium-induced cell death [23], which critically contributes to AD progression in humans and animal models [25–26,27,76].

4. Summary and overview

The present review highlights the challenges of understanding the biological function of LTCCs given their complexity. While their structures are still being illuminated, it is apparent that functionally, they are very complex and only a fraction of their biological functions have been revealed thus far. Despite their complexity, drugs targeting LTCCs have been used clinically to regulate calcium dysregulation in the heart and to manage pain. LTCC mediated calcium dysregulation has been implicated in both aging and AD, with overexpression and increased activity of these channels. However, a critical gap in knowledge remains regarding how LTCCs are upregulated in AD and how hyperfunction of LTCCs relates to neurotoxicity. LTCC blockers such as nimodipine can ameliorate the cognitive decline in animal models. However, LTCC blockers have limited and variable effects in clinical studies. The clinical ineffectiveness of LTCC blockers may be due to unfavorable side effects. Alternately, the reversal of LTCC-mediated AD pathology could be stage-dependent. Targeting early preclinical stages may prove to be more beneficial.

While the complete mechanistic understanding of the effects of A β on LTCCs is still lacking, the role of pathological tau, especially pre-tangle tau has drawn more attention given its early appearance in human brains. One hypothesis is that SFKs, specifically Src and Pyk2 kinase, are involved in pre-tangle tau mediation of LTCC hyperfunction. As indicated earlier, LTCCs are functionally up-regulated in diseased brains, and this further enhances phosphorylation by SFKs creating a positive feedback loop that leads to a dangerous intracellular calcium overload. Besides LTCC overexpression and hyperfunction-induced pathological changes, LTCCs have numerous physiological functions. Thus, finding alternative therapeutic strategies that can specifically target patholog-

ical up-regulation of Cav1.2 in the brain may be a more promising approach than targeting the channel itself.

Funding

This work was supported by a Natural Sciences and Engineering Research Council of Canada grant (RGPIN-2018-04401) to QY, a Canadian Institutes of Health Research project grant (#PJT-169197) to QY and an Aging Research Center – Newfoundland and Labrador research grant to VR. CAC was funded by a Canadian Institutes of Health Research Canada Graduate Scholarship (CGS-M).

CRedit authorship contribution statement

Chelsea A. Crossley: Conceptualization, Writing – original draft, Writing – review & editing. **Vishaal Rajani:** Conceptualization, Visualization, Writing – review & editing, Funding acquisition. **Qi Yuan:** Conceptualization, Supervision, Visualization, Writing – original draft, Writing – review & editing, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

- [1] Abeti R, Abramov AY. Mitochondrial Ca^{2+} in neurodegenerative disorders. *Pharmacol Res* 2015;99:377–81. <https://doi.org/10.1016/j.phrs.2015.05.007>.
- [2] Abiria SA, Colbran RJ. CaMKII associates with Cav1.2 L-type calcium channels via selected beta subunits to enhance regulatory phosphorylation. *J Neurochem* 2010;112(1):150–61. <https://doi.org/10.1111/j.1471-4159.2009.06436.x>.
- [3] Ahljianian MK, Westenbroek RE, Catterall WA. Subunit structure and localization of dihydropyridine-sensitive calcium channels in mammalian brain, spinal cord, and retina. *Neuron* 1990;4(6):819–32. [https://doi.org/10.1016/0896-6273\(90\)90135-3](https://doi.org/10.1016/0896-6273(90)90135-3).
- [4] Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* 2011;1812(12):1584–90. <https://doi.org/10.1016/j.bbadis.2011.08.013>.
- [5] Arikath J, Campbell KP. Auxiliary subunits: essential components of the voltage-gated calcium channel complex. *Curr Opin Neurobiol* 2003;13(3):298–307. [https://doi.org/10.1016/s0959-4388\(03\)00066-7](https://doi.org/10.1016/s0959-4388(03)00066-7).
- [6] Awasthi A, Ramachandran B, Ahmed S, Benito E, Shinoda Y, Nitzan N, et al. Synaptotagmin-3 drives AMPA receptor endocytosis, depression of synapse strength, and forgetting. *Science* 2019;363(6422). <https://doi.org/10.1126/science.aav1483>.
- [7] Balijepalli RC, Foell JD, Hall DD, Hell JW, Kamp TJ. Localization of cardiac L-type Ca^{2+} channels to a caveolar macromolecular signaling complex is required for beta(2)-adrenergic regulation. *PNAS* 2006;103(19):7500–5. <https://doi.org/10.1073/pnas.0503465103>.
- [8] Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, et al. Nimodipine in the treatment of old age dementias. *Prog Neuropsychopharmacol Biol Psychiatry* 1990;14(4):525–51. [https://doi.org/10.1016/0278-5846\(90\)90005-2](https://doi.org/10.1016/0278-5846(90)90005-2).
- [9] Bannister RA, Beam KG. Ca^{2+} : The atypical prototypical voltage-gated Ca^{2+} channel. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* 2013;1828(7):1587–97. <https://doi.org/10.1016/j.bbame.2012.09.007>.
- [10] Barclay J, Balaguero N, Mione M, Ackerman SL, Letts VA, Brodbeck J, et al. Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the *Ca_v2d2* gene and decreased calcium channel current in cerebellar Purkinje cells. *J Neurosci* 2001;21(16):6095–104.
- [11] Bech-Hansen NT, Naylor MJ, Maybaum TA, Pearce WG, Koop B, Fishman GA, et al. Loss-of-function mutations in a calcium-channel alpha1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness. *Nat Genet* 1998;19(3):264–7. <https://doi.org/10.1038/947>.
- [12] Bence-Hanulec KK, Marshall J, Blair LA. Potentiation of neuronal L calcium channels by IGF-1 requires phosphorylation of the alpha1 subunit on a specific tyrosine residue. *Neuron* 2000;27(1):121–31. [https://doi.org/10.1016/s0896-6273\(00\)00014-3](https://doi.org/10.1016/s0896-6273(00)00014-3).
- [13] Benitah JP, Alvarez JL, Gomez AM. L-type Ca^{2+} current in ventricular cardiomyocytes. *J Mol Cell Cardiol* 2010;48(1):26–36. <https://doi.org/10.1016/j.yimcc.2009.07.026>.

- [14] Bhaskar K, Yen SH, Lee G. Disease-related modifications in tau affect the interaction between Fyn and Tau. *J Biol Chem* 2005;280(42):35119–25. <https://doi.org/10.1074/jbc.M505895200>.
- [15] Bichet D, Cornet V, Geib S, Carlier E, Volsen S, Hoshi T, et al. The I-II loop of the Ca²⁺ channel alpha1 subunit contains an endoplasmic reticulum retention signal antagonized by the beta subunit. *Neuron* 2000;25(1):177–90. [https://doi.org/10.1016/s0896-6273\(00\)80881-8](https://doi.org/10.1016/s0896-6273(00)80881-8).
- [16] Blalock EM, Porter NM, Landfield PW. Decreased G-protein-mediated regulation and shift in calcium channel types with age in hippocampal cultures. *J Neurosci* 1999;19(19):8674–84.
- [17] Booth CA, Ridler T, Murray TK, Ward MA, de Groot E, Goodfellow M, et al. Electrical and Network Neuronal Properties Are Preferentially Disrupted in Dorsal, But Not Ventral, Medial Entorhinal Cortex in a Mouse Model of Tauopathy. *J Neurosci* 2016;36(2):312–24. <https://doi.org/10.1523/JNEUROSCI.2845-14.2016>.
- [18] Booth CA, Witton J, Nowacki J, Tsaneva-Atanasova K, Jones MW, Randall AD, et al. Altered Intrinsic Pyramidal Neuron Properties and Pathway-Specific Synaptic Dysfunction Underlie Aberrant Hippocampal Network Function in a Mouse Model of Tauopathy. *J Neurosci* 2016;36(2):350–63. <https://doi.org/10.1523/JNEUROSCI.2151-15.2016>.
- [19] Boric K, Munoz P, Gallagher M, & Kirkwood A. (2008). Potential adaptive function for altered long-term potentiation mechanisms in aging hippocampus. *Journal of Neuroscience*, 28(32), 8034–8039. doi: 28/32/8034 [pii] 10.1523/JNEUROSCI.2036-08.2008.
- [20] Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. *J NeuroPathol Exp Neurol* 2011;70(11):960–9. <https://doi.org/10.1097/NFN.0b013e318232a379>.
- [21] Bradley J, Finkbeiner S. An evaluation of specificity in activity-dependent gene expression in neurons. *Prog Neurobiol* 2002;67(6):469–77. [https://doi.org/10.1016/s0301-0082\(02\)00047-3](https://doi.org/10.1016/s0301-0082(02)00047-3).
- [22] Bray JG, Myrlieff M. Involvement of protein kinase C and protein kinase A in the enhancement of L-type calcium current by GABAB receptor activation in neonatal hippocampus. *Neuroscience* 2011;179:62–72. <https://doi.org/10.1016/j.neuroscience.2011.01.054>.
- [23] Britti E, Ros J, Esteras N, Abramov AY. Tau inhibits mitochondrial calcium efflux and makes neurons vulnerable to calcium-induced cell death. *Cell Calcium* 2020;86. <https://doi.org/10.1016/j.ceca.2019.102150>.
- [24] Brunden KR, Trojanowski JQ, Lee VM. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. *J Alzheimers Dis* 2008;14(4):393–9. <https://doi.org/10.3233/jad-2008-14406>.
- [25] Calvo-Rodriguez M, Bacskai BJ. High mitochondrial calcium levels precede neuronal death in vivo in Alzheimer's disease. *Cell Stress* 2020;4(7):187–90. <https://doi.org/10.15698/cst2020.07.226>.
- [26] Calvo-Rodriguez M, Bacskai BJ. Mitochondrial and Calcium in Alzheimer's Disease: From Cell Signaling to Neuronal Cell Death. *Trends Neurosci* 2021;44(2):136–51. <https://doi.org/10.1016/j.tins.2020.10.004>.
- [27] Calvo-Rodriguez M, Hou SS, Snyder AC, Kharitonova EK, Russ AN, Das S, et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer's disease. *Nat Commun* 2020;11(1):2146. <https://doi.org/10.1038/s41467-020-16074-2>.
- [28] Campbell LW, Hao SY, Thibault O, Blalock EM, Landfield PW. Aging changes in voltage-gated calcium currents in hippocampal CA1 neurons. *J Neurosci* 1996;16(19):6286–95.
- [29] Catterall WA. Structure and regulation of voltage-gated Ca²⁺ channels. *Annu Rev Cell Dev Biol* 2000;16:521–55. <https://doi.org/10.1146/annurev.cellbio.16.1.521>.
- [30] Chanda B, Bezanilla F. A common pathway for charge transport through voltage-sensing domains. *Neuron* 2008;57(3):345–51. <https://doi.org/10.1016/j.neuron.2008.01.015>.
- [31] Chen RS, Deng TC, Garcia T, Sellers ZM, Best PM. Calcium channel gamma subunits: a functionally diverse protein family. *Cell Biochem Biophys* 2007;47(2):178–86. <https://doi.org/10.1007/s12013-007-0002-0>.
- [32] Cheng RCK, Tikhonov DB, Zhorov BS. Structural model for phenylalkylamine binding to L-type calcium channels. *J Biol Chem* 2009;284(41):28332–42. <https://doi.org/10.1074/jbc.M109.027326>.
- [33] Coon AL, Wallace DR, Mactutus CF, Booze RM. L-type calcium channels in the hippocampus and cerebellum of Alzheimer's disease brain tissue. *Neurobiol Aging* 1999;20(6):597–603. [https://doi.org/10.1016/S0197-4580\(99\)00068-8](https://doi.org/10.1016/S0197-4580(99)00068-8).
- [34] Copenhagen PF, Anekonda TS, Musashe D, Robinson KM, Ramaker JM, Swanson TL, et al. A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. *Dis Model Mech* 2011;4(5):634–48. <https://doi.org/10.1242/dmm.006841>.
- [35] Daschil N, Kniewallner KM, Obermair GJ, Hutter-Paier B, Windisch M, Marksteiner J, et al. L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model. *Neurobiol Aging* 2015;36(3):1333–41. <https://doi.org/10.1016/j.neurobiolaging.2014.12.027>.
- [36] Daschil N, Obermair GJ, Flucher BE, Stefanova N, Hutter-Paier B, Windisch M, et al. CaV1.2 calcium channel expression in reactive astrocytes is associated with the formation of amyloid-beta plaques in an Alzheimer's disease mouse model. *J Alzheimers Dis* 2013;37(2):439–51. <https://doi.org/10.3233/JAD-130560>.
- [37] Davare MA, Avdonin V, Hall DD, Peden EM, Burette A, Weinberg RJ, et al. A beta2 adrenergic receptor signaling complex assembled with the Ca²⁺ channel Cav1.2. *Science* 2001;293(5527):98–101. <https://doi.org/10.1126/science.293.5527.98>.
- [38] Davare MA, Hell JW. Increased phosphorylation of the neuronal L-type Ca(2+) channel Ca(v)1.2 during aging. *PNAS* 2003;100(26):16018–23. <https://doi.org/10.1073/pnas.2236970100>.
- [39] Davidson RM, Shajenko L, Donta TS. Amyloid beta-peptide (A beta P) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells. *Brain Res* 1994;643(1–2):324–7. [https://doi.org/10.1016/0006-8993\(94\)90041-8](https://doi.org/10.1016/0006-8993(94)90041-8).
- [40] Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. *Trends Pharmacol Sci* 2007;28(5):220–8. <https://doi.org/10.1016/j.tips.2007.03.005>.
- [41] Deisseroth K, Mermelstein PG, Xia H, Tsien RW. Signaling from synapse to nucleus: the logic behind the mechanisms. *Curr Opin Neurobiol* 2003;13(3):354–65. [https://doi.org/10.1016/s0959-4388\(03\)00076-x](https://doi.org/10.1016/s0959-4388(03)00076-x).
- [42] Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. *Nature* 1996;383(6600):547–50. <https://doi.org/10.1038/383547a0>.
- [43] Disterhoft JF, Moyer Jr JR, Thompson LT. The calcium rationale in aging and Alzheimer's disease. Evidence from an animal model of normal aging. *Ann NY Acad Sci* 1994;747:382–406. <https://doi.org/10.1111/j.1749-6632.1994.tb44424.x>.
- [44] Disterhoft JF, Oh MM. Alterations in intrinsic neuronal excitability during normal aging. *Aging Cell* 2007;6(3):327–36. <https://doi.org/10.1111/j.1474-9726.2007.00297.x>.
- [45] Disterhoft JF, Thompson LT, Moyer Jr JR, Mogul DJ. Calcium-dependent afterhyperpolarization and learning in young and aging hippocampus. *Life Sci* 1996;59(5–6):413–20.
- [46] Disterhoft JF, Wu WW, Ohno M. Biophysical alterations of hippocampal pyramidal neurons in learning, ageing and Alzheimer's disease. *Ageing Res Rev* 2004;3(4):383–406. <https://doi.org/10.1016/j.arr.2004.07.001>.
- [47] Dolmetsch RE, Pajvani U, Fife K, Spotts JM, Greenberg ME. Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. *Science* 2001;294(5541):333–9. <https://doi.org/10.1126/science.1063395>.
- [48] Dolphin AC. Calcium channel diversity: multiple roles of calcium channel subunits. *Curr Opin Neurobiol* 2009;19(3):237–44. <https://doi.org/10.1016/j.conb.2009.06.006>.
- [49] Dolphin AC. The alpha2delta subunits of voltage-gated calcium channels. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* 2013;1828(7):1541–9. <https://doi.org/10.1016/j.bbame.2012.11.019>.
- [50] Donato R, Page KM, Koch D, Nieto-Rostro M, Foucault I, Davies A, et al. The ducky(2) mutation in Ca_v2d2 results in reduced spontaneous Purkinje cell activity and altered gene expression. *J Neurosci* 2006;26(48):12576–86. <https://doi.org/10.1523/JNEUROSCI.3080-06.2006>.
- [51] Dubuis E, Rockliffe N, Hussain M, Boyett M, Wray D, Gawler D. Evidence for multiple Src binding sites on the alpha1c L-type Ca²⁺ channel and their roles in activity regulation. *Cardiovasc Res* 2006;69(2):391–401. <https://doi.org/10.1016/j.cardiores.2005.11.006>.
- [52] Dzhura I, Wu Y, Colbran RJ, Balsler JR, Anderson ME. Calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels. *Nat Cell Biol* 2000;2(3):173–7. <https://doi.org/10.1038/35004052>.
- [53] Ekinci FJ, Malik KU, Shea TB. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. *J Biol Chem* 1999;274(42):30322–7. <https://doi.org/10.1074/jbc.274.42.30322>.
- [54] Endoh T. Involvement of Src tyrosine kinase and mitogen-activated protein kinase in the facilitation of calcium channels in rat nucleus of the tractus solitarius by angiotensin II. *J Physiol* 2005;568(Pt 3):851–65. <https://doi.org/10.1113/jphysiol.2005.095307>.
- [55] Esteras N, Abramov AY. Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology. *Cells* 2020;9(9). <https://doi.org/10.3390/cells9092135>.
- [56] Evans GJ, Pocock JM. Modulation of neurotransmitter release by dihydropyridine-sensitive calcium channels involves tyrosine phosphorylation. *Eur J Neurosci* 1999;11(1):279–92. <https://doi.org/10.1046/j.1460-9568.1999.00427.x>.
- [57] Fischhof PK, Wagner G, Littschauer L, Ruther E, Apecechea M, Hiersemenzel R, et al. Therapeutic results with nimodipine in primary degenerative dementia and multi-infarct dementia. In: Bergener M, Reisberg B, editors. *Diagnosis & Treatment of Senile Dementia*. Berlin: Springer-Verlag; 1989. p. 350–9.
- [58] Fisher RE, Gray R, Johnston D. Properties and distribution of single voltage-gated calcium channels in adult hippocampal neurons. *J Neurophysiol* 1990;64(1):91–104. <https://doi.org/10.1152/jn.1990.64.1.91>.
- [59] Flucher BE. Skeletal muscle CaV1.1 channelopathies. *Pflügers Arch* 2020;472(7):739–54. <https://doi.org/10.1007/s00424-020-02368-3>.
- [60] Foster TC. Dissecting the age-related decline on spatial learning and memory tasks in rodent models: N-methyl-D-aspartate receptors and voltage-dependent Ca²⁺ channels in senescent synaptic plasticity. *Prog Neurobiol* 2012;96(3):283–303. <https://doi.org/10.1016/j.pneurobio.2012.01.007>.
- [61] Foster TC, Norris CM. Age-associated changes in Ca(2+)-dependent processes: relation to hippocampal synaptic plasticity. *Hippocampus* 1997;7(6):602–12.

- [https://doi.org/10.1002/\(SICI\)1098-1063\(1997\)7:6<602::AID-HIPO3>3.0.CO;2-G](https://doi.org/10.1002/(SICI)1098-1063(1997)7:6<602::AID-HIPO3>3.0.CO;2-G).
- [62] Freise D, Held B, Wissenbach U, Pfeifer A, Trost C, Himmerkus N, et al. Absence of the gamma subunit of the skeletal muscle dihydropyridine receptor increases L-type Ca²⁺ currents and alters channel inactivation properties. *J Biol Chem* 2000;275(19):14476–81. <https://doi.org/10.1074/jbc.275.19.14476>.
- [63] Furukawa K, Wang Y, Yao PJ, Fu W, Mattson MP, Itoyama Y, et al. Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. *J Neurochem* 2003;87(2):427–36. <https://doi.org/10.1046/j.1471-4159.2003.02020.x>.
- [64] Gao T, Yatani A, Dell'Acqua ML, Sako H, Green SA, Dascal N, et al. cAMP-dependent regulation of cardiac L-type Ca²⁺ channels requires membrane targeting of PKA and phosphorylation of channel subunits. *Neuron* 1997;19(1):185–96. [https://doi.org/10.1016/s0896-6273\(00\)80358-x](https://doi.org/10.1016/s0896-6273(00)80358-x).
- [65] Gui P, Wu X, Ling S, Stotz SC, Winkfein RJ, Wilson E, et al. Integrin receptor activation triggers converging regulation of Cav1.2 calcium channels by c-Src and protein kinase A pathways. *J Biol Chem* 2006;281(20):14015–25. <https://doi.org/10.1074/jbc.M600433200>.
- [66] Hall DD, Feekes JA, Arachchige Don AS, Shi M, Hamid J, Chen L, et al. Binding of protein phosphatase 2A to the L-type calcium channel Cav1.2 next to Ser 1928, its main PKA site, is critical for Ser1928 dephosphorylation. *Biochemistry* 2006;45(10):3448–59. <https://doi.org/10.1021/bi051593z>.
- [67] Harraz OF, Jensen LJ. Vascular calcium signalling and ageing. *J Physiol* 2021;599(24):5361–77. <https://doi.org/10.1113/jp280950>.
- [68] Hell JW, Westenbroek RE, Warner C, Ahljianian MK, Prystay W, Gilbert MM, et al. Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. *J Cell Biol* 1993;123(4):949–62. <https://doi.org/10.1083/jcb.123.4.949>.
- [69] Hering S, Zangerl-Plessl EM, Beyl S, Hohaus A, Andranovits S, Timin EN. Calcium channel gating. *Pflügers Arch* 2018;470(9):1291–309. <https://doi.org/10.1007/s00424-018-2163-7>.
- [70] Higham JP, Hidalgo S, Buhl E, Hodge JLL. Restoration of Olfactory Memory in Drosophila Overexpressing Human Alzheimer's Disease Associated Tau by Manipulation of L-Type Ca²⁺ Channels. *Front Cell Neurosci* 2019;13:409. <https://doi.org/10.3389/fncel.2019.00409>.
- [71] Hou, X. Y., Zhang, G. Y., Yan, J. Z., & Liu, Y. (2003). Increased tyrosine phosphorylation of alpha(1C) subunits of L-type voltage-gated calcium channels and interactions among Src/Fyn, PSD-95 and alpha(1C) in rat hippocampus after transient brain ischemia. *Brain Research*, 979(1-2), 43-50. doi: S0006899303028452 [pii].
- [72] Hu XQ, Singh N, Mukhopadhyay D, Akbarali HI. Modulation of voltage-dependent Ca²⁺ channels in rabbit colonic smooth muscle cells by c-Src and focal adhesion kinase. *J Biol Chem* 1998;273(9):5337–42. <https://doi.org/10.1074/jbc.273.9.5337>.
- [73] Hudmon A, Schulman H, Kim J, Maltez JM, Tsien RW, Pitt GS. CaMKII tethers to L-type Ca²⁺ channels, establishing a local and dedicated integrator of Ca²⁺ signals for facilitation. *J Cell Biol* 2005;171(3):537–47. <https://doi.org/10.1083/jcb.200505155>.
- [74] Hutchinson TE, Zhong W, Chebolu S, Wilson SM, Darmani NA. L-type calcium channels contribute to 5-HT₃-receptor-evoked CaMKIIalpha and ERK activation and induction of emesis in the least shrew (*Cryptotis parva*). *Eur J Pharmacol* 2015;755:110–8. <https://doi.org/10.1016/j.ejphar.2015.02.042>.
- [75] Iadecola C, Gottesman RF. Cerebrovascular Alterations in Alzheimer Disease. *Circ Res* 2018;123(4):406–8. <https://doi.org/10.1161/CIRCRESAHA.118.313400>.
- [76] Jadiya P, Kolmetzky DW, Tomar D, Di Meco A, Lombardi AA, Lambert JP, et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. *Nat Commun* 2019;10(1):3885. <https://doi.org/10.1038/s41467-019-11813-6>.
- [77] Jiang LH, Gawler DJ, Hodson N, Milligan CJ, Pearson HA, Porter V, et al. Regulation of cloned cardiac L-type calcium channels by cGMP-dependent protein kinase. *J Biol Chem* 2000;275(9):6135–43. <https://doi.org/10.1074/jbc.275.9.6135>.
- [78] Jin N, Yin X, Yu D, Cao M, Gong CX, Iqbal K, et al. Truncation and activation of GSK-3beta by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. *Sci Rep* 2015;5:8187. <https://doi.org/10.1038/srep08187>.
- [79] Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unerstall JR. Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. *J Neurochem* 1989;53(6):1772–81. <https://doi.org/10.1111/j.1471-4159.1989.tb09242.x>.
- [80] Kang MG, Chen CC, Felix R, Letts VA, Frankel WN, Mori Y, et al. Biochemical and biophysical evidence for gamma 2 subunit association with neuronal voltage-activated Ca²⁺ channels. *J Biol Chem* 2001;276(35):32917–24. <https://doi.org/10.1074/jbc.M100787200>.
- [81] Kavalali ET, Hwang KS, Plummer MR. cAMP-dependent enhancement of dihydropyridine-sensitive calcium channel availability in hippocampal neurons. *J Neurosci* 1997;17(14):5334–48.
- [82] Khachaturian, Z. S. (1984). Towards theories of brain aging. In D. W. K. Kay & G. D. Burrows (Eds.), *Handbook of studies on psychiatry and old age* (pp. 7–30). New York: Elsevier: Amsterdam.
- [83] Khachaturian ZS. Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. *Ann N Y Acad Sci* 1989;568:1–4. <https://doi.org/10.1111/j.1749-6632.1989.tb12485.x>.
- [84] Khachaturian ZS. The role of calcium regulation in brain aging: reexamination of a hypothesis. *Aging (Milano)* 1989;1(1):17–34. <https://doi.org/10.1007/BF03323872>.
- [85] Kim S, Rhim H. Effects of amyloid-beta peptides on voltage-gated L-type Ca (V)1.2 and Ca(V)1.3 Ca(2+) channels. *Mol Cells* 2011;32(3):289–94. <https://doi.org/10.1007/s10059-011-0075-x>.
- [86] Kim YS, Kim YB, Kim WB, Lee SW, Oh SB, Han HC, et al. Histamine 1 receptor-Gbetagamma-cAMP/PKA-CFTR pathway mediates the histamine-induced resetting of the suprachiasmatic circadian clock. *Mol Brain* 2016;9(1):49. <https://doi.org/10.1186/s13041-016-0227-1>.
- [87] Koschak A, Fernandez-Quintero ML, Heigl T, Ruzza M, Seitter H, Zanetti L. Cav1.4 dysfunction and congenital stationary night blindness type 2. *Pflügers Arch* 2021;473(9):1437–54. <https://doi.org/10.1007/s00424-021-02570-x>.
- [88] Kumar A. NMDA Receptor Function During Senescence: Implication on Cognitive Performance. *Front Neurosci* 2015;9:473. <https://doi.org/10.3389/fnins.2015.00473>.
- [89] Lacinova L, Hofmann F. Ca²⁺- and voltage-dependent inactivation of the expressed L-type Ca(v)1.2 calcium channel. *Arch Biochem Biophys* 2005;437(1):42–50. <https://doi.org/10.1016/j.abb.2005.02.025>.
- [90] Landfield PW. 'Increased calcium-current' hypothesis of brain aging. *Neurobiol Aging* 1987;8(4):346–7. [https://doi.org/10.1016/0197-4580\(87\)90074-1](https://doi.org/10.1016/0197-4580(87)90074-1).
- [91] Lee G. Tau and src family tyrosine kinases. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* 2005;1739(2–3):323–30. <https://doi.org/10.1016/j.bbadis.2004.09.002>.
- [92] Lee HK, Min SS, Gallagher M, Kirkwood A. NMDA receptor-independent long-term depression correlates with successful aging in rats. *Nat Neurosci* 2005;8(12):1657–9. <https://doi.org/10.1038/nn1586>.
- [93] Lee TS, Karl R, Moosmang S, Lenhardt P, Klugbauer N, Hofmann F, et al. Calmodulin kinase II is involved in voltage-dependent facilitation of the L-type Ca²⁺ calcium channel: Identification of the phosphorylation sites. *J Biol Chem* 2006;281(35):25560–7. <https://doi.org/10.1074/jbc.M508661200>.
- [94] Letts VA, Felix R, Biddlecome GH, Arikath J, Mahaffey CL, Valenzuela A, et al. The mouse stargazer gene encodes a neuronal Ca²⁺-channel gamma subunit. *Nat Genet* 1998;19(4):340–7. <https://doi.org/10.1038/1228>.
- [95] Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, et al. Protein tyrosine kinase PYK2 involved in Ca²⁺-induced regulation of ion channel and MAP kinase functions. *Nature* 1995;376(6543):737–45. <https://doi.org/10.1038/376737a0>.
- [96] Li C, Gotz J. Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn. *J Alzheimers Dis* 2018;64(1):205–21. <https://doi.org/10.3233/JAD-180054>.
- [97] Li Y, Yang H, He T, Zhang L, Liu C. Post-Translational Modification of Cav1.2 and its Role in Neurodegenerative Diseases. *Front Pharmacol* 2021;12:12. <https://doi.org/10.3389/fphar.2021.775087>.
- [98] Lima PA, Marrion NV. Mechanisms underlying activation of the slow AHP in rat hippocampal neurons. *Brain Res* 2007;1150:74–82. <https://doi.org/10.1016/j.brainres.2007.02.067>.
- [99] Lipscombe D, Helton TD, Xu W. L-type calcium channels: the low down. *J Neurophysiol* 2004;92(5):2633–41. <https://doi.org/10.1152/jn.00486.2004>.
- [100] Lisman J, Schulman H, Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. *Nat Rev Neurosci* 2002;3(3):175–90. <https://doi.org/10.1038/nrn753>.
- [101] Liu Y, Hou XY, Zhang GY, Xu TL. L-type voltage-gated calcium channel attends regulation of tyrosine phosphorylation of NMDA receptor subunit 2A induced by transient brain ischemia. *Brain Res* 2003;972(1–2):142–8. [https://doi.org/10.1016/s0006-8993\(03\)02519-8](https://doi.org/10.1016/s0006-8993(03)02519-8).
- [102] Lopez JR, Lyckman A, Oddo S, Laferla FM, Querfurth HW, Shtifman A. Increased intraneuronal resting [Ca²⁺] in adult Alzheimer's disease mice. *J Neurochem* 2008;105(1):262–71. <https://doi.org/10.1111/j.1471-4159.2007.05135.x>.
- [103] Mahapatra S, Marcantoni A, Zuccotti A, Carabelli V, Carbone E. Equal sensitivity of Cav1.2 and Cav1.3 channels to the opposing modulations of PKA and PKG in mouse chromaffin cells. *J Physiol* 2012;590(20):5053–73. <https://doi.org/10.1113/jphysiol.2012.236729>.
- [104] Martin-Aragon Baudel M, Flores-Tamez VA, Hong J, Reddy GR, Maillard P, Burns AE, et al. Spatiotemporal Control of Vascular CaV1.2 by alpha1C S1928 Phosphorylation. *Circ Res* 2022. <https://doi.org/10.1161/CIRCRESAHA.122.321479>.
- [105] Marx JH. Alzheimer's disease. A new take on tau *Science* 2007;316(5830):1416–7. <https://doi.org/10.1126/science.316.5830.1416>.
- [106] Matthews EA, Linardakis JM, Disterhoft JF. The fast and slow afterhyperpolarizations are differentially modulated in hippocampal neurons by aging and learning. *J Neurosci* 2009;29(15):4750–5. <https://doi.org/10.1523/JNEUROSCI.0384-09.2009>.
- [107] Maziar A, Critch T, Ghosh S, Rajani V, Flynn CM, Qin T, et al. Aging differentially affects LTCC function in hippocampal CA1 and piriform cortex pyramidal neurons. *Cereb Cortex* 2022. <https://doi.org/10.1093/cercor/bhac152>.
- [108] McHugh D, Sharp EM, Scheuer T, Catterall WA. Inhibition of cardiac L-type calcium channels by protein kinase C phosphorylation of two sites in the N-terminal domain. *PNAS* 2000;97(22):12334–8. <https://doi.org/10.1073/pnas.210384297>.
- [109] Michalska P, Mayo P, Fernandez-Mendivil C, Tenti G, Duarte P, Buendia I, et al. Antioxidant, Anti-inflammatory and Neuroprotective Profiles of Novel 1,4-

- Dihydropyridine Derivatives for the Treatment of Alzheimer's Disease. Antioxidants (Basel) 2020;9(8). <https://doi.org/10.3390/antiox9080650>.
- [110] Morgans CW. Calcium channel heterogeneity among cone photoreceptors in the tree shrew retina. *Eur J Neurosci* 1999;11(8):2989–93. <https://doi.org/10.1046/j.1460-9568.1999.00719.x>.
- [111] Morgans CW, El Far O, Berntson A, Wassle H, Taylor WR. Calcium extrusion from mammalian photoreceptor terminals. *J Neurosci* 1998;18(7):2467–74.
- [112] Morotti S, Grandi E, Summa A, Ginsburg KS, Bers DM. Theoretical study of L-type Ca(2+) current inactivation kinetics during action potential repolarization and early afterdepolarizations. *J Physiol* 2012;590(18):4465–81. <https://doi.org/10.1113/jphysiol.2012.231886>.
- [113] Moyer Jr JR, Power JM, Thompson LT, Disterhoft JF. Increased excitability of aged rabbit CA1 neurons after trace eyeblink conditioning. *J Neurosci* 2000;20(14):5476–82.
- [114] Moyer Jr JR, Thompson LT, Black JP, Disterhoft JF. Nimodipine increases excitability of rabbit CA1 pyramidal neurons in an age- and concentration-dependent manner. *J Neurophysiol* 1992;68(6):2100–9. <https://doi.org/10.1152/jn.1992.68.6.2100>.
- [115] Navakkode S, Liu C, Soong TW. Altered function of neuronal L-type calcium channels in ageing and neuroinflammation: Implications in age-related synaptic dysfunction and cognitive decline. *Ageing Res Rev* 2018;42:86–99. <https://doi.org/10.1016/j.arr.2018.01.001>.
- [116] Nunez-Santana FL, Oh MM, Antion MD, Lee A, Hell JW, Disterhoft JF. Surface L-type Ca2+ channel expression levels are increased in aged hippocampus. *Aging Cell* 2014;13(1):111–20. <https://doi.org/10.1111/acel.12157>.
- [117] Nystoriak MA, Nieves-Cintrón M, Patriarchi T, Buonarati OR, Prada MP, Morotti S, et al. Ser 1928 phosphorylation by PKA stimulates the L-type Ca2+ channel Cav1.2 and vasoconstriction during acute hyperglycemia and diabetes. *Sci Signal* 2017;10(463). <https://doi.org/10.1126/scisignal.aaf9647>.
- [118] Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron* 2003;39(3):409–21. [https://doi.org/10.1016/s0896-6273\(03\)00434-3](https://doi.org/10.1016/s0896-6273(03)00434-3).
- [119] Oh MM, Oliveira FA, Disterhoft JF. Learning and aging related changes in intrinsic neuronal excitability. *Front Aging Neurosci* 2010;2:2. <https://doi.org/10.3389/fnuro.2010.002.2010>.
- [120] Ortner NJ, Striessnig J. L-type calcium channels as drug targets in CNS disorders. *Channels (Austin)* 2016;10(1):7–13. <https://doi.org/10.1080/19336950.2015.1048936>.
- [121] Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, et al. Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier. *Mol Med* 2011;17(3–4):149–62. <https://doi.org/10.2119/molmed.2010.00180>.
- [122] Patriarchi T, Qian H, Di Biase V, Malik ZA, Chowdhury D, Price JL, et al. Phosphorylation of Cav1.2 on S1928 uncouples the L-type Ca2+ channel from the beta2A adrenergic receptor. *EMBO J* 2016;35(12):1330–45. <https://doi.org/10.15252/embj.201593409>.
- [123] Peterson BZ, DeMaria CD, Adelman JP, Yue DT. Calmodulin is the Ca2+ sensor for Ca2+-dependent inactivation of L-type calcium channels. *Neuron* 1999;22(3):549–58. [https://doi.org/10.1016/s0896-6273\(00\)80709-6](https://doi.org/10.1016/s0896-6273(00)80709-6).
- [124] Pitt GS. Calmodulin and CaMKII as molecular switches for cardiac ion channels. *Cardiovasc Res* 2007;73(4):641–7. <https://doi.org/10.1016/j.cardiores.2006.10.019>.
- [125] Polydorou M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. *J Neurosci* 2009;29(34):10741–9. <https://doi.org/10.1523/JNEUROSCI.10665-09.2009>.
- [126] Power JM, Wu WW, Sametsky E, Oh MM, Disterhoft JF. Age-related enhancement of the slow outward calcium-activated potassium current in hippocampal CA1 pyramidal neurons in vitro. *Journal of Neuroscience* 2002;22(16):7234–43. doi: 20026641.
- [127] Puri TS, Gerhardtstein BL, Zhao XL, Ladner MB, Hosey MM. Differential effects of subunit interactions on protein kinase A- and C-mediated phosphorylation of L-type calcium channels. *Biochemistry* 1997;36(31):9605–15. <https://doi.org/10.1021/Bi970500d>.
- [128] Qian H, Patriarchi T, Price JL, Matt L, Lee B, Nieves-Cintrón M, et al. Phosphorylation of Ser 1928 mediates the enhanced activity of the L-type Ca2+ channel Cav1.2 by the beta2A-adrenergic receptor in neurons. *Sci Signal* 2017;10(463). <https://doi.org/10.1126/scisignal.aaf9659>.
- [129] Rajani V, Maziar A, Man KNM, Hell JW, Yuan Q. Age-Dependent Contributions of NMDA Receptors and L-Type Calcium Channels to Long-Term Depression in the Piriform Cortex. *Int J Mol Sci* 2021;22(24). <https://doi.org/10.3390/ijms222413551>.
- [130] Ramirez-Latorre JA. Functional upregulation of Ca(2+)-activated K(+) channels in the development of substantia nigra dopamine neurons. *PLoS One* 2012;7(12):e51610.
- [131] Richards MW, Butcher AJ, Dolphin AC. Ca2+ channel beta-subunits: structural insights AID our understanding. *Trends Pharmacol Sci* 2004;25(12):626–32. <https://doi.org/10.1016/j.tips.2004.10.008>.
- [132] Rios E, Brum G. Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle. *Nature* 1987;325(6106):717–20. <https://doi.org/10.1038/325717a0>.
- [133] Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. *Am J Geriatr Psychiatry* 2008;16(11):883–92. <https://doi.org/10.1097/JGP.0b013e318181276a>.
- [134] Rosenzweig ES, Barnes CA. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. *Prog Neurobiol* 2003;69(3):143–79. [https://doi.org/10.1016/s0301-0082\(02\)00126-0](https://doi.org/10.1016/s0301-0082(02)00126-0).
- [135] Sabri A, Govindarajan G, Griffin TM, Byron KL, Samarel AM, Lucchesi PA. Calcium- and protein kinase C-dependent activation of the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle. *Circ Res* 1998;83(8):841–51. <https://doi.org/10.1161/01.res.83.8.841>.
- [136] Sanderson JL, Freund RK, Gorski JA, Dell'Acqua ML. beta-Amyloid disruption of LTP/LTD balance is mediated by AKAP150-anchored PKA and Calcineurin regulation of Ca(2+)-permeable AMPA receptors. *Cell Rep* 2021;37(1). <https://doi.org/10.1016/j.celrep.2021.109786>.
- [137] Santos SF, Pierrot N, Morel N, Gailly P, Sindic C, Octave JN. Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. *J Neurosci* 2009;29(15):4708–18. <https://doi.org/10.1523/JNEUROSCI.4917-08.2009>.
- [138] Schultz D, Mikala G, Yatani A, Engle DB, Iles DE, Segers B, et al. Cloning, chromosomal localization, and functional expression of the alpha 1 subunit of the L-type voltage-dependent calcium channel from normal human heart. *PNAS* 1993;90(13):6228–32. <https://doi.org/10.1073/pnas.90.13.6228>.
- [139] Schuster A, Lacinova L, Klugbauer N, Ito H, Birnbaumer L, Hofmann F. The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamines. *EMBO J* 1996;15(10):2365–70.
- [140] Scragg JL, Fearon IM, Boyle JP, Ball SG, Varadi G, Peers C. Alzheimer's amyloid peptides mediate hypoxic up-regulation of L-type Ca2+ channels. *FASEB J* 2005;19(1):150–2. <https://doi.org/10.1096/fj.04-2659fje>.
- [141] Sculptoreanu A, Rotman E, Takahashi M, Scheuer T, Catterall WA. Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. *PNAS* 1993;90(21):10135–9. <https://doi.org/10.1073/pnas.90.21.10135>.
- [142] Sculptoreanu A, Scheuer T, Catterall WA. Voltage-dependent potentiation of L-type Ca2+ channels due to phosphorylation by cAMP-dependent protein kinase. *Nature* 1993;364(6434):240–3. <https://doi.org/10.1038/364240a0>.
- [143] Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* 2008;14(8):837–42. <https://doi.org/10.1038/nm1782>.
- [144] Shankar S, Teyler TJ, Robbins N. Aging differentially alters forms of long-term potentiation in rat hippocampal area CA1. *J Neurophysiol* 1998;79(1):334–41. <https://doi.org/10.1152/jn.1998.79.1.334>.
- [145] Shimomura T, Yonekawa Y, Nagura H, Tateyama M, Fujiyoshi Y, Irie K. A native prokaryotic voltage-dependent calcium channel with a novel selectivity filter sequence. *Elife (Cambridge)* 2020;9. <https://doi.org/10.7554/elife.52828>.
- [146] Simms BA, Zamponi GW. Trafficking and stability of voltage-gated calcium channels. *Cell Mol Life Sci* 2012;69(6):843–56. <https://doi.org/10.1007/s00018-011-0843-y>.
- [147] Stan GF, Church TW, Randall E, Harvey JRM, Brown JT, Wilkinson KA, et al. Tau isoform-specific enhancement of L-type calcium current and augmentation of afterhyperpolarization in rat hippocampal neurons. *Sci Rep* 2022;12(1):15231. <https://doi.org/10.1038/s41598-022-18648-0>.
- [148] Strauss O, Mergler S, Wiederholt M. Regulation of L-type calcium channels by protein tyrosine kinase and protein kinase C in cultured rat and human retinal pigment epithelial cells. *FASEB J* 1997;11(11):859–67. <https://doi.org/10.1096/fasebj.11.11.9285484>.
- [149] Striessnig J, Bolz HJ, Koschak A. Channelopathies in Cav1.1, Cav1.3, and Cav1.4 voltage-gated L-type Ca2+ channels. *Pflügers Arch* 2010;460(2):361–74. <https://doi.org/10.1007/s00424-010-0800-x>.
- [150] Striessnig J, Grabner M, Mitterdorfer J, Hering S, Sinnegger MJ, Glossmann H. Structural basis of drug binding to L Ca2+ channels. *Trends Pharmacol Sci* 1998;19(3):108–15. [https://doi.org/10.1016/s0165-6147\(98\)01171-7](https://doi.org/10.1016/s0165-6147(98)01171-7).
- [151] Takahashi M, Seagar MJ, Jones JF, Reber BF, Catterall WA. Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle. *PNAS* 1987;84(15):5478–82. <https://doi.org/10.1073/pnas.84.15.5478>.
- [152] Tanabe T, Takeshima H, Mikami A, Flockerzi V, Takahashi H, Kangawa K, et al. Primary structure of the receptor for calcium channel blockers from skeletal muscle. *Nature* 1987;328(6128):313–8. <https://doi.org/10.1038/328313a0>.
- [153] Tang L, Gamal El-Din TM, Payandeh J, Martinez GQ, Heard TM, Scheuer T, et al. Structural basis for Ca2+ selectivity of a voltage-gated calcium channel. *Nature* 2014;505(7481):56–61. <https://doi.org/10.1038/nature12775>.
- [154] Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin—calcium channel alpha2-delta [Cavalpha2-delta] ligands. *Pain* 2009;142(1–2):13–6. <https://doi.org/10.1016/j.pain.2008.11.019>.
- [155] Taylor H. B. C., Emptage, N. J., & Jeans A. F. (2021). Long-term depression links amyloid-beta to the pathological hyperphosphorylation of tau. *Cell Reports*, 36(9). doi: Artn 109638.10.1016/j.celrep.2021.109638.
- [156] J.L. Taylor H.A.T. Pritchard K.R. Walsh P. Strangward C. White D. Hill-Eubanks et al. Functionally linked potassium channel activity in cerebral endothelial and smooth muscle cells is compromised in Alzheimer's disease. *Proc Natl Acad Sci U S A* 119 26 2022 10.1073/pnas.2204581119 e2204581119.
- [157] Thibault O, Gant JC, Landfield PW. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. *Aging Cell* 2007;6(3):307–17. <https://doi.org/10.1111/j.1474-9726.2007.00295.x>.

- [158] Thibault O, Hadley R, Landfield PW. Elevated postsynaptic [Ca²⁺]_i and L-type calcium channel activity in aged hippocampal neurons: relationship to impaired synaptic plasticity. *J Neurosci* 2001;21(24):9744–56.
- [159] Thibault O, Landfield PW. Increase in single L-type calcium channels in hippocampal neurons during aging. *Science* 1996;272(5264):1017–20.
- [160] Thibault O, Pancani T, Landfield PW, Norris CM. Reduction in neuronal L-type calcium channel activity in a double knock-in mouse model of Alzheimer's disease. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* 2012;1822(4):546–9. <https://doi.org/10.1016/j.bbadis.2012.01.004>.
- [161] Thompson LT, Deyo RA, Disterhoft JF. Nimodipine enhances spontaneous activity of hippocampal pyramidal neurons in aging rabbits at a dose that facilitates associative learning. *Brain Res* 1990;535(1):119–30. [https://doi.org/10.1016/0006-8993\(90\)91830-a](https://doi.org/10.1016/0006-8993(90)91830-a).
- [162] Tikhonov DB, Zhorov BS. Molecular modeling of benzothiazepine binding in the L-type calcium channel. *J Biol Chem* 2008;283(25):17594–604. <https://doi.org/10.1074/jbc.M800141200>.
- [163] Tikhonov DB, Zhorov BS. Structural model for dihydropyridine binding to L-type calcium channels. *J Biol Chem* 2009;284(28):19006–17. <https://doi.org/10.1074/jbc.M109.011296>.
- [164] Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. *Biol Psychiatry* 1990;27(10):1133–42. [https://doi.org/10.1016/0006-3223\(90\)90050-c](https://doi.org/10.1016/0006-3223(90)90050-c).
- [165] Tracy TE, Madero-Perez J, Swaney DL, Chang TS, Moritz M, Konrad C, et al. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. *Cell* 2022;185(4):712–728 e714. <https://doi.org/10.1016/j.cell.2021.12.041>.
- [166] Ueda K, Shinohara S, Yagami T, Asakura K, Kawasaki K. Amyloid beta protein potentiates Ca²⁺ influx through L-type voltage-sensitive Ca²⁺ channels: a possible involvement of free radicals. *J Neurochem* 1997;68(1):265–71. <https://doi.org/10.1046/j.1471-4159.1997.68010265.x>.
- [167] Vandal DH, Mahapatra S, Calorio C, Marcantoni A, Carbone E. Cav1.3 and Cav1.2 channels of adrenal chromaffin cells: emerging views on cAMP/cGMP-mediated phosphorylation and role in pacemaking. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* 2013;1828(7):1608–18. <https://doi.org/10.1016/j.bbame.2012.11.013>.
- [168] Veng LM, Mesches MH, Browning MD. Age-related working memory impairment is correlated with increases in the L-type calcium channel protein alpha1D (Cav1.3) in area CA1 of the hippocampus and both are ameliorated by chronic nimodipine treatment. *Brain Res Mol Brain Res* 2003;110(2):193–202. [https://doi.org/10.1016/s0169-328x\(02\)00643-5](https://doi.org/10.1016/s0169-328x(02)00643-5).
- [169] Voskobiyuk Y, Roth JR, Cochran JN, Rush T, Carullo NV, Mesina JS, et al. Alzheimer's disease risk gene BIN1 induces Tau-dependent network hyperexcitability. *Elife (Cambridge)* 2020;9. <https://doi.org/10.7554/eLife.57354>.
- [170] Wang D, Govindaiah G, Liu R, De Arcangelis V, Cox CL, Xiang YK. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. *FASEB J* 2010;24(9):3511–21. <https://doi.org/10.1096/fj.10-156661>.
- [171] Wang HG, George MS, Kim J, Wang C, Pitt GS. Ca²⁺/calmodulin regulates trafficking of Ca(V)₁.2 Ca²⁺ channels in cultured hippocampal neurons. *J Neurosci* 2007;27(34):9086–93. <https://doi.org/10.1523/JNEUROSCI.1720-07.2007>.
- [172] Wang Y, Mattson MP. L-type Ca²⁺ currents at CA1 synapses, but not CA3 or dentate granule neuron synapses, are increased in 3xTgAD mice in an age-dependent manner. *Neurobiol Aging* 2014;35(1):88–95. <https://doi.org/10.1016/j.neurobiolaging.2013.07.007>.
- [173] Webster NJ, Ramsden M, Boyle JP, Pearson HA, Peers C. Amyloid peptides mediate hypoxic increase of L-type Ca²⁺ channels in central neurones. *Neurobiol Aging* 2006;27(3):439–45. <https://doi.org/10.1016/j.neurobiolaging.2005.02.002>.
- [174] West AE, Chen WG, Dalva MB, Dolmetsch RE, Kornhauser JM, Shaywitz AJ, et al. Calcium regulation of neuronal gene expression. *PNAS* 2001;98(20):11024–31. <https://doi.org/10.1073/pnas.191352298>.
- [175] Wild AR, Sinnen BL, Dittmer PJ, Kennedy MJ, Sather WA, Dell'Acqua ML. Synapse-to-Nucleus Communication through NFAT Is Mediated by L-type Ca²⁺ Channel Ca²⁺ Spike Propagation to the Soma. *Cell Rep* 2019;26(13):3537–3550 e3534. <https://doi.org/10.1016/j.celrep.2019.03.005>.
- [176] Willis M, Kaufmann WA, Wietzorrek G, Hutter-Paier B, Moosmang S, Humpel C, et al. L-type calcium channel Ca_v1.2 in transgenic mice overexpressing human AbetaPP751 with the London (V717I) and Swedish (K670M/N671L) mutations. *J Alzheimers Dis* 2010;20(4):1167–80. <https://doi.org/10.3233/JAD-2010-091117>.
- [177] Wisely EV, Xiang YK, Oddo S. Genetic suppression of beta2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. *Hum Mol Genet* 2014;23(15):4024–34. <https://doi.org/10.1093/hmg/ddu116>.
- [178] Wu J, Yan Z, Li Z, Yan C, Lu S, Dong M, et al. Structure of the voltage-gated calcium channel Cav1.1 complex. *Science* 2015;350(6267):aad2395. <https://doi.org/10.1126/science.aad2395>.
- [179] Xiao RP, Cheng H, Lederer WJ, Suzuki T, Lakatta EG. Dual regulation of Ca²⁺/calmodulin-dependent kinase II activity by membrane voltage and by calcium influx. *PNAS* 1994;91(20):9659–63. <https://doi.org/10.1073/pnas.91.20.9659>.
- [180] Xu L, Sun LL, Xie LX, Mou SZ, Zhang DW, Zhu JY, et al. Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling. *Curr Med Chem* 2021;28(3):514–24. <https://doi.org/10.2174/0929867327666200714154059>.
- [181] Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. *Neuron* 2007;53(3):337–51. <https://doi.org/10.1016/j.neuron.2007.01.010>.
- [182] Yu JT, Tan L, Ou JR, Zhu JX, Liu K, Song JH, et al. Polymorphisms at the beta2-adrenergic receptor gene influence Alzheimer's disease susceptibility. *Brain Res* 2008;1210:216–22. <https://doi.org/10.1016/j.brainres.2008.03.019>.
- [183] Yue Y, Qu Y, Boutjdir M. Beta- and alpha-adrenergic cross-signaling for L-type Ca current is impaired in transgenic mice with constitutive activation of epsilonPKC. *Biochem Biophys Res Commun* 2004;314(3):749–54. <https://doi.org/10.1016/j.bbrc.2003.12.155>.
- [184] Zuhlke RD, Pitt GS, Deisseroth K, Tsien RW, Reuter H. Calmodulin supports both inactivation and facilitation of L-type calcium channels. *Nature* 1999;399(6732):159–62. <https://doi.org/10.1038/20200>.
- [185] Anderson ME, Braun AP, Shulman H, Premack BA. Multifunctional Ca²⁺/calmodulin-dependent protein kinase mediates Ca²⁺-induced enhancement of the L-type Ca₂₊ current in rabbit ventricular myocytes. *Circ Res* 1994;75(5):854–61.
- [186] Yuan W, Bers DM. Ca-dependent facilitation of cardiac Ca current is due to Ca-calmodulin-dependent protein kinase. *Am J Physiol* 1994;267(3 Pt 2):H982–993.